Darren O Brien

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

Alphaeon 1 LLC operates as investment holding company. The company was founded in 2020 and is headquartered in Newport Beach, CA.

Alphaeon 1 LLC operates as investment holding company. The company was founded in 2020 and is headquartered in Newport Beach, CA.

Sailing Capital Advisors Hong Kong Ltd (Sailing Capital Advisors) is a private equity subsidiary of Sailing Capital Management Co Ltd founded in 2012. The firm is headquartered in Wan Chain, Hong Kong.

Sailing Capital Advisors Hong Kong Ltd (Sailing Capital Advisors) is a private equity subsidiary of Sailing Capital Management Co Ltd founded in 2012. The firm is headquartered in Wan Chain, Hong Kong.

Sailing Capital Advisors Hong Kong Ltd (Sailing Capital Advisors) is a private equity subsidiary of Sailing Capital Management Co Ltd founded in 2012. The firm is headquartered in Wan Chain, Hong Kong.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

Sailing Capital Advisors Hong Kong Ltd (Sailing Capital Advisors) is a private equity subsidiary of Sailing Capital Management Co Ltd founded in 2012. The firm is headquartered in Wan Chain, Hong Kong.

Sailing Capital Advisors Hong Kong Ltd (Sailing Capital Advisors) is a private equity subsidiary of Sailing Capital Management Co Ltd founded in 2012. The firm is headquartered in Wan Chain, Hong Kong.

Sailing Capital Advisors Hong Kong Ltd (Sailing Capital Advisors) is a private equity subsidiary of Sailing Capital Management Co Ltd founded in 2012. The firm is headquartered in Wan Chain, Hong Kong.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.

AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA.